Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same authorSame journal

Functional Suitability Evaluation of Radioimmunoconjugates of Nanobodies against PD-L1 and HER2/neu for Tumor Theranostics.

Sovremennye tekhnologii v meditsine·2026
Same author

Pathomorphological Features of Lung Damage Caused by Infection with Various Variants of SARS-CoV-2 in Humanized Model Animals.

Doklady. Biochemistry and biophysics·2026
Same author

Specific Matrix on the Basis of Angiotensin-Converting Enzyme 2: Development and Functional Analysis.

Bulletin of experimental biology and medicine·2025
Same author

Heterologous Production of Antimicrobial Peptides in Yeast Allows for Massive Assessment of the Activity of DNA-Encoded Antimicrobials In Situ.

Acta naturae·2025
Same author

Detection and Quantification of Polymorphic MICA and MICB Molecules in Immunoassays: Initial Insights.

HLA·2025
Same author

Platforms for the Search for New Antimicrobial Agents Using In Vivo C. elegans Models.

Acta naturae·2025

相关实验视频

Updated: May 29, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

225

细胞模型用于测试针对人类PD-L1的药物.

O A Shashkova1, L A Terekhina2, I S Malakhov3

  • 1PhD, Senior Researcher, Hybridoma Technology Laboratory; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia.

Sovremennye tekhnologii v meditsine
|February 3, 2025
PubMed
概括
此摘要是机器生成的。

一种新的细胞模型CT26-PD-L1被开发用于测试抗人类PD-L1剂. 该模型有效地评估了治疗和诊断剂在体外和体内环境中的特异性.

关键词:
CT26 CT26 在线观看在PD-L1中.这就是VHH VHH.细胞模型 细胞模型无线电连合物是一种无线电连合物.有针对性的代理商.瘤模型 瘤模型

更多相关视频

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

14.2K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.6K

相关实验视频

Last Updated: May 29, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

225
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

14.2K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.6K

科学领域:

  • 生物技术是生物技术.
  • 免疫学 免疫学 免疫学
  • 在瘤学瘤学.

背景情况:

  • 在癌症治疗中,针对编程死亡连接体1 (PD-L1) 的向疗法的开发至关重要.
  • 评估抗PD-L1剂的现有模型需要复杂的基础设施或缺乏全面的测试能力.

研究的目的:

  • 创建和验证一种基因工程细胞模型,用于评估抗人类PD-L1治疗和诊断剂的特异性.
  • 建立一个强大的平台,用于体外和体内对PD-L1向剂的评估.

主要方法:

  • 基因改造的小鼠CT26癌细胞 (CT26-PD-L1) 被创建以表达人类PD-L1.
  • 使用实时PCR和流细胞计证实了PD-L1表达.
  • 该模型使用放射性同位素结合抗PD-L1纳米体进行了体外和体内特异性和内化研究的测试.

主要成果:

  • CT26-PD-L1细胞系成功地表达了人类的PD-L1,并在小鼠中形成了瘤.
  • 在体内研究表明CT26-PD-L1瘤中放射性免疫结合物的特定积累,但在对照CT26瘤中没有.
  • 在体外实验证实了CT26-PD-L1细胞对抗PD-L1纳米体的内部化.

结论:

  • 开发的CT26-PD-L1细胞模型适用于体外和体内对抗人类PD-L1剂特异性的测试.
  • 该模型为新型PD-L1向治疗和诊断的临床前评估提供了有价值的工具.
  • 该模型有助于在单个试验中确认药物特异性和量化标结合分数.